These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 37730833)
21. Nasal delivery of broadly neutralizing antibodies protects mice from lethal challenge with SARS-CoV-2 delta and omicron variants. Lu J; Yin Q; Pei R; Zhang Q; Qu Y; Pan Y; Sun L; Gao D; Liang C; Yang J; Wu W; Li J; Cui Z; Wang Z; Li X; Li D; Wang S; Duan K; Guan W; Liang M; Yang X Virol Sin; 2022 Apr; 37(2):238-247. PubMed ID: 35527227 [TBL] [Abstract][Full Text] [Related]
22. Dynamics of viral shedding during ancestral or Omicron BA.1 SARS-CoV-2 infection and enhancement of pre-existing immunity during breakthrough infections. Saade C; Brengel-Pesce K; Gaymard A; Trabaud MA; Destras G; Oriol G; Cheynet V; Debombourg M; Mokdad B; Billaud G; Oblette A; Créhalet H; Giannoli JM; Garrigou C; Generenaz L; Compagnon C; Boibieux A; Lina B; Morfin F; Pozzetto B; Josset L; Trouillet-Assant S; Bal A Emerg Microbes Infect; 2022 Dec; 11(1):2423-2432. PubMed ID: 36098494 [TBL] [Abstract][Full Text] [Related]
23. Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination. Silva ARD; Villas-Boas LS; Tozetto-Mendoza TR; Honorato L; Paula A; Witkin SS; Mendes-Correa MC Rev Inst Med Trop Sao Paulo; 2022; 64():e19. PubMed ID: 35239863 [TBL] [Abstract][Full Text] [Related]
24. Identification and Analysis of Monoclonal Antibodies with Neutralizing Activity against Diverse SARS-CoV-2 Variants. Ishimaru H; Nishimura M; Tjan LH; Sutandhio S; Marini MI; Effendi GB; Shigematsu H; Kato K; Hasegawa N; Aoki K; Kurahashi Y; Furukawa K; Shinohara M; Nakamura T; Arii J; Nagano T; Nakamura S; Sano S; Iwata S; Okamura S; Mori Y J Virol; 2023 Jun; 97(6):e0028623. PubMed ID: 37191569 [TBL] [Abstract][Full Text] [Related]
25. Immune responses in COVID-19 patients during breakthrough infection with SARS-CoV-2 variants Delta, Omicron-BA.1 and Omicron-BA.5. Bormann M; Brochhagen L; Alt M; Otte M; Thümmler L; van de Sand L; Kraiselburd I; Thomas A; Gosch J; Braß P; Ciesek S; Widera M; Dolff S; Dittmer U; Witzke O; Meyer F; Lindemann M; Schönfeld A; Rohn H; Krawczyk A Front Immunol; 2023; 14():1150667. PubMed ID: 37520539 [TBL] [Abstract][Full Text] [Related]
26. SARS-CoV-2 Antibodies in Commercial Immunoglobulin Products Show Markedly Reduced Cross-reactivities Against Omicron Variants. Lindahl H; Chen P; Åberg M; Ljunggren HG; Buggert M; Aleman S; Smith CIE; Bergman P J Clin Immunol; 2023 Aug; 43(6):1075-1082. PubMed ID: 37058198 [TBL] [Abstract][Full Text] [Related]
27. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial. Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177 [TBL] [Abstract][Full Text] [Related]
28. Ancestral SARS-CoV-2 and Omicron BA.5-specific neutralizing antibody and T-cell responses after Omicron bivalent booster vaccination in previously infected and infection-naive individuals. Mak WA; Visser W; van der Vliet M; Markus HY; Koeleman JGM; Ong DSY J Med Virol; 2023 Aug; 95(8):e28989. PubMed ID: 37565645 [TBL] [Abstract][Full Text] [Related]
29. SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against Omicron subvariants BA.1, BA.2 and BA.5 and can be predicted by anti-S antibody concentrations in serological assays. Seidel A; Hoffmann S; Jahrsdörfer B; Körper S; Ludwig C; Vieweg C; Albers D; von Maltitz P; Müller R; Lotfi R; Wuchter P; Klüter H; Kirchhoff F; Schmidt M; Münch J; Schrezenmeier H Front Immunol; 2023; 14():1170759. PubMed ID: 37180152 [TBL] [Abstract][Full Text] [Related]
30. Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants. Seki Y; Yoshihara Y; Nojima K; Momose H; Fukushi S; Moriyama S; Wagatsuma A; Numata N; Sasaki K; Kuzuoka T; Yato Y; Takahashi Y; Maeda K; Suzuki T; Mizukami T; Hamaguchi I Med; 2022 Jun; 3(6):406-421.e4. PubMed ID: 35815933 [TBL] [Abstract][Full Text] [Related]
31. Broadly neutralizing human antibodies against Omicron subvariants of SARS-CoV-2. Chiang HL; Liang KH; Lu RM; Kuo TW; Lin YL; Wu HC J Biomed Sci; 2023 Jul; 30(1):59. PubMed ID: 37525188 [TBL] [Abstract][Full Text] [Related]
32. Intranasal Boosting with Spike Fc-RBD of Wild-Type SARS-CoV-2 Induces Neutralizing Antibodies against Omicron Subvariants and Reduces Viral Load in the Nasal Turbinate of Mice. Cai JP; Luo C; Wang K; Cao H; Chen LL; Zhang X; Han Y; Yin F; Zhang AJ; Chu H; Yuan S; Kok KH; To KK; Chen H; Chen Z; Jin DY; Yuen KY; Chan JF Viruses; 2023 Mar; 15(3):. PubMed ID: 36992395 [TBL] [Abstract][Full Text] [Related]
33. Egg-Derived Anti-SARS-CoV-2 Immunoglobulin Y (IgY) With Broad Variant Activity as Intranasal Prophylaxis Against COVID-19. Frumkin LR; Lucas M; Scribner CL; Ortega-Heinly N; Rogers J; Yin G; Hallam TJ; Yam A; Bedard K; Begley R; Cohen CA; Badger CV; Abbasi SA; Dye JM; McMillan B; Wallach M; Bricker TL; Joshi A; Boon ACM; Pokhrel S; Kraemer BR; Lee L; Kargotich S; Agochiya M; John TS; Mochly-Rosen D Front Immunol; 2022; 13():899617. PubMed ID: 35720389 [TBL] [Abstract][Full Text] [Related]
34. Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial. Corominas J; Garriga C; Prenafeta A; Moros A; Cañete M; Barreiro A; González-González L; Madrenas L; Güell I; Clotet B; Izquierdo-Useros N; Raïch-Regué D; Gallemí M; Blanco J; Pradenas E; Trinité B; Prado JG; Blanch-Lombarte O; Pérez-Caballero R; Plana M; Esteban I; Pastor-Quiñones C; Núñez-Costa X; Taleb RA; McSkimming P; Soriano A; Nava J; Anagua JO; Ramos R; Lluch RM; Comes AC; Romero SO; Gomez XM; Sans-Pola C; Moltó J; Benet S; Bailón L; Arribas JR; Borobia AM; Parada JQ; Navarro-Pérez J; Forner Giner MJ; Lucas RO; Jiménez MDMV; Compán SO; Alvarez-Mon M; Troncoso D; Arana-Arri E; Meijide S; Imaz-Ayo N; García PM; de la Villa Martínez S; Fernández SR; Prat T; Torroella È; Ferrer L Lancet Reg Health Eur; 2023 May; 28():100613. PubMed ID: 37131861 [TBL] [Abstract][Full Text] [Related]
35. Nanobodies with cross-neutralizing activity provide prominent therapeutic efficacy in mild and severe COVID-19 rodent models. Han Q; Wang S; Wang Z; Zhang C; Wang X; Feng N; Wang T; Zhao Y; Chi H; Yan F; Xia X Virol Sin; 2023 Oct; 38(5):787-800. PubMed ID: 37423308 [TBL] [Abstract][Full Text] [Related]
36. Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Zhu F; Zhuang C; Chu K; Zhang L; Zhao H; Huang S; Su Y; Lin H; Yang C; Jiang H; Zang X; Liu D; Pan H; Hu Y; Liu X; Chen Q; Song Q; Quan J; Huang Z; Zhong G; Chen J; Han J; Sun H; Cui L; Li J; Chen Y; Zhang T; Ye X; Li C; Wu T; Zhang J; Xia NS Lancet Respir Med; 2022 Aug; 10(8):749-760. PubMed ID: 35644168 [TBL] [Abstract][Full Text] [Related]
37. Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients. Benning L; Morath C; Bartenschlager M; Kim H; Reineke M; Beimler J; Buylaert M; Nusshag C; Kälble F; Reichel P; Töllner M; Schaier M; Klein K; Benes V; Rausch T; Rieger S; Stich M; Tönshoff B; Weidner N; Schnitzler P; Zeier M; Süsal C; Hien Tran T; Bartenschlager R; Speer C Am J Transplant; 2022 Jul; 22(7):1873-1883. PubMed ID: 35384272 [TBL] [Abstract][Full Text] [Related]
38. A nasal omicron vaccine booster elicits potent neutralizing antibody response against emerging SARS-CoV-2 variants. Lam JY; Ng YY; Yuen CK; Wong WM; Yuen KY; Kok KH Emerg Microbes Infect; 2022 Dec; 11(1):964-967. PubMed ID: 35275039 [TBL] [Abstract][Full Text] [Related]
39. Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection. Americo JL; Cotter CA; Earl PL; Liu R; Moss B Proc Natl Acad Sci U S A; 2022 Jun; 119(24):e2202069119. PubMed ID: 35679343 [TBL] [Abstract][Full Text] [Related]
40. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose. Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I Front Immunol; 2023; 14():1099246. PubMed ID: 36756112 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]